AHN-12 Biodistribution in Advanced Leukemia

Phase 1

Terminated

• Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
• Interventions: Biological: 90Y-AHN-12

• Registration Number: NCT01207076
• Lead Sponsor: Masonic Cancer Center, University of Minnesota

Brief Summary

This study is a single institution phase I study for the treatment of patients with relapsed or refractory leukemia aged 12 years and older using 90Y-AHN-12.

Detailed Description

A dose escalation schema will be used with the initial patient receiving the current lowest dose of nonradiolabeled AHN-12 (from 0.20 mg/kg to 1.0 mg/kg). If a favorable biodistribution is not achieved and the patient remains negative for HAMA, the infusion may be repeated up to two more times (with a one level increase in nonradiolabeled AHN-12 each time) in an attempt of achieving favorable biodistribution.

In order to achieve the primary objective of identifying the optimal nonradiolabeled dose of AHN-12 antibody for all patients, if the first patient at the current antibody dose does not achieve favorable biodistribution, the next patient(s) will be treated at the next higher dose level.

Patients achieving favorable biodistribution and remaining negative for HAMA will be eligible for the therapeutic component of this trial. Those not meeting these requirements will be taken off study and followed.

Study Timeline

• Study First Submitted: 2010-09-21
• Study First Submitted QC: 2010-09-21
• Study First Posted: 2010-09-22
• Study Start: 2013-12
• Primary Completion: 2014-07
• Study Completion: 2014-07
• Status Verified: 2017-12
• Last Update Submitted: 2017-12-03
• Last Update Posted: 2017-12-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Patients must have one of the following histologically confirmed CD45+ diseases. If possible, AHN-12 positivity will be confirmed by flow cytometry on a recent bone marrow or a peripheral blood sample, if circulating blasts are present.

  • Acute myelogenous leukemia (AML), primary refractory or relapsed disease
  • Refractory myelodysplastic syndrome (MDS)
  • AML arising from pre-existing MDS, refractory
  • Acute lymphoblastic leukemia (ALL), primary refractory or relapsed disease
  • Chronic myelogenous leukemia (CML) following blast crisis

• Age ≥ 12 years

• Karnofsky Performance Status ≥ 60% (16 years and older) or Lansky Play Score ≥ 60 (<16 years)

• Life expectancy of > 12 weeks in the opinion of the enrolling medical provider

• Patients must have adequate organ function

• Human anti-mouse antibody (HAMA) must be negative (perform on all patients regardless of prior therapies).

• Consent to adequate contraception. The effects of 90Y-AHN-12 on the developing fetus are unknown.

• Source of allogeneic stem cells must have been identified in event of severe myelosuppression

• Able to give written consent.

• Both men and women of all ethnic groups are eligible for this trial.

Exclusion Criteria

• Ongoing grade 2 or greater non-hematologic toxicity due to previously administered therapies
• < 8 days from completion of therapy with any biologic agent
• Receiving any investigational agents
• Active central nervous system (CNS) leukemia are excluded from this clinical trial
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-AHN-12 or other agents used in study.
• Uncontrolled illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the enrolling medical provider.
• Pregnant and breastfeeding women are excluded from this study because 90Y-AHN-12, being radioactive, as well as high dose chemotherapy and total body irradiation (TBI) have the potential for teratogenic or abortifacient effects.
• Human immunodeficiency virus (HIV) positive patients:
• < 60 days since an autologous transplant
• Bone marrow cellularity <5% (because of concern of myelosuppression)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
receiving AHN-12 and 90Y-AHN-12	90Y-AHN-12	Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).

Primary Outcome Measures

Name	Time	Method
Optimal Dose of AHN-12 Non-radiolabeled Antibody	Day 2	doses of nonradiolabeled antibody are specified: 0.20, 0.40, 0.60, 0.80 and 1.00 mg/kg.

Secondary Outcome Measures

Name	Time	Method
Human Anti-Mouse Antibody (HAMA) Response	30 and 90 Days Post Therapy, Then Every 6 Months If Positive	Event is whether or not the patient develops a HAMA response.
Anti-tumor Activity of 90Y-AHN-12	30 and 90 Days Post Therapy	Event is response to therapy: complete remission, partial remission, refractory or relapsed disease.
Maximum Tolerated Dose (MTD) of 90Y-AHN-12	Within 14 days of achieving favorable biodistribution	•Determine the MTD of 90Y-AHN-12 for patients with a favorable biodistribution and a negative human anti-mouse antibody (HAMA). Doses of radiolabeled antibody are specified starting dose level with dose increment of 2 gray (Gy) to maximum of 22 Gy.

Trial Locations

Locations (1)

Masonic Cancer Center, University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States